Related Experiment Video
Updated: May 9, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Improving outcomes of patients with pancreatic cancer
Stephan B Dreyer1,2,3, Philip Beer1,4, Sunil R Hingorani5,6
1Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow, UK.
Abstract:
Research studies aimed at improving the outcomes of patients with pancreatic ductal adenocarcinoma (PDAC) have brought about limited progress, and in clinical practice, the optimized use of surgery, chemotherapy and supportive care have led to modest improvements in survival that have probably reached a plateau. As a result, PDAC is expected to be the second leading cause of cancer-related death in Western societies within a decade. The development of therapeutic advances in PDAC has been challenging owing to a lack of actionable molecular targets, a typically immunosuppressive microenvironment, and a disease course characterized by rapid progression and clinical deterioration. Yet, the progress in our understanding of PDAC and identification of novel therapeutic opportunities over the past few years is leading to a strong sense of optimism in the field. In this Perspective, we address the aforementioned challenges, including biological aspects of PDAC that make this malignancy particularly difficult to treat. We explore specific areas with potential for therapeutic advances, including targeting mutant KRAS, novel strategies to harness the antitumour immune response and approaches to early detection, and propose mechanisms to improve clinical trial design and to overcome various community and institutional barriers to progress.
Insights
Pancreatic ductal adenocarcinoma (PDAC) remains a deadly cancer with limited treatment progress. New research offers optimism by exploring novel therapeutic strategies and early detection for improved patient outcomes.
Area of Science:
- Oncology
- Cancer Research
- Translational Medicine
Background:
- Pancreatic ductal adenocarcinoma (PDAC) presents significant challenges in improving patient outcomes, with current treatments yielding modest survival gains.
- PDAC is projected to become the second leading cause of cancer-related death in Western countries within ten years.
- Therapeutic development is hindered by a lack of actionable targets, an immunosuppressive tumor microenvironment, and rapid disease progression.
Purpose of the Study:
- To address the challenges in treating PDAC.
- To explore novel therapeutic avenues for PDAC.
- To propose improvements in clinical trial design and overcome barriers to progress.
Main Methods:
- Review of current research on PDAC biology and treatment.
- Identification of potential therapeutic targets and strategies.
- Analysis of factors impeding clinical trial success.
Main Results:
- Limited progress in PDAC treatment necessitates new approaches.
- Emerging understanding of PDAC biology reveals potential therapeutic targets.
- Novel strategies targeting mutant KRAS and the immune response show promise.
Conclusions:
- Despite challenges, recent advances foster optimism for PDAC treatment.
- Targeting specific molecular pathways, enhancing immune response, and early detection are key areas for advancement.
- Improving clinical trial design and addressing systemic barriers are crucial for future progress.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:21Cancer Survival Analysis